Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRHR1 | P34998 | 11/20 | 0.39 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.32 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.32 |
| ▸ | P2RX7 | Q99572 | 4/20 | 0.31 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.31 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2192196 | 0.95 | CRHR1 (0.41) | CRHR1HDAC1PKMCHRM1ADORA2A | |
| SCHEMBL2192396 | 0.90 | CRHR1 (0.42) | CRHR1HDAC1PKMCHRM1P2RX7 | |
| SCHEMBL2189328 | 0.88 | CRHR1 (0.41) | CRHR1P2RX7 | |
| SCHEMBL2191943 | 0.88 | CRHR1 (0.38) | CRHR1HDAC1P2RX7 | |
| SCHEMBL2191591 | 0.87 | CRHR1 (0.39) | CRHR1HDAC1P2RX7 | |
| SCHEMBL2190344 | 0.86 | CRHR1 (0.44) | CRHR1HDAC1PKMCHRM1KLKB1 | |
| SCHEMBL2191579 | 0.85 | CRHR1 (0.42) | CRHR1HDAC1PKMP2RX7 | |
| SCHEMBL2192416 | 0.84 | CRHR1 (0.39) | CRHR1HDAC1 | |
| SCHEMBL2193279 | 0.84 | CRHR1 (0.36) | CRHR1HDAC1 | |
| SCHEMBL2195976 | 0.84 | CRHR1 (0.36) | CRHR1HDAC1P2RX7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110172255-A1 | Condensed N-Heterocyclic Compounds and their Use as CRF Receptor Antagonists | SB PHARMCO PUERTO RICO INC | 2011-07-14 | — | — | US | disclosed |
| US-7427630-B2 | Condensed N-heterocyclic compounds and their use as CRF receptor antagonists | SB PHARMACO PUERTO RICO INC. (US) | 2008-09-23 | — | — | US | disclosed |
| US-20070004708-A1 | Condensed n-heterocyclic compounds and their use as crf receptor antagonists | NEUROCRINE BIOSCIENCES, INC. | 2007-01-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110172255-A1 | Condensed N-Heterocyclic Compounds and their Use as CRF Receptor Antagonists | CRH, CRHR1, CRHR2 | CRHR1 2/4885HDAC1 595/4885PKM 2146/4885 |
| US-20070004708-A1 | Condensed n-heterocyclic compounds and their use as crf receptor antagonists | CRHR2, NR3C2, CRHR1 | CRHR1 3/4885HDAC1 1114/4885PKM 2307/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.